The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Apellis Pharmaceuticals Inc’s current trading price is -58.33% away from its 52-week high, while its distance from the 52-week low is -0.81%. The stock’s price range for this period has been between $31.00 and $73.80 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 2.64 million for the day, a number notably higher than the average daily volume of 1.58 million over the last three months.
The market performance of Apellis Pharmaceuticals Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $73.80 on 01/09/24, while the lowest value for the same duration was $31.00 on 09/24/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Apellis Pharmaceuticals Inc (APLS) has experienced a quarterly decline of -23.89% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.74B and boasts a workforce of 706 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 39.18, with a change in price of -15.30. Similarly, Apellis Pharmaceuticals Inc recorded 1,504,168 in trading volume during the last 100 days, posting a change of -33.22%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for APLS stands at 1.80. Similarly, the long-term debt-to-equity ratio is also 1.77.
APLS Stock Stochastic Average
Apellis Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 0.09%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 0.09%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 9.87% and 14.02%, respectively.
APLS Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. The metric has seen a significant loss of -48.63% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -44.62%. Over the past 30 days, the price of APLS has leaped by -23.34%. And in the last five days, it has fallen by -13.45%.
